Latest / Decera Clinical Education Oncology Podcast
Precision Therapy in Lung Cancer: FAQ on Biomarkers for Immune Checkpoint Inhibitors
In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced non-small-cell lung cancer with topics including:
Selecting therapy for advanced NSCLC without actionable mutations and with different levels of PD-L1 expression
Choosing therapy for advanced NSCLC with an actionable mutation on NGS and high PD-L1 expression
Leveraging key data from CheckMate 9LA to identify patients who may benefit from chemotherapy plus nivolumab/ipilimumab
STK11/KEAP1 as potential…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.